CYP2C19 metabolizer phenotypes may affect the efficacy of statins on lowering small dense low-density lipoprotein cholesterol of patients with coronary artery disease

BACKGROUND: Dyslipidemia is a major cause of arteriosclerotic cardiovascular disease (ASCVD), and low-density lipoprotein cholesterol (LDL-C) is the profile to be reduced to prevent disease progression. Small dense low-density lipoprotein cholesterol (sdLDL-C) has been proven to be a more effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Ruozhu, Zhao, Xiaoyu, Zhuo, Huilin, Wang, Wei, Xu, Yue, Hu, Zixin, Zhang, Tiexu, Zhao, Jiangman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806256/
https://www.ncbi.nlm.nih.gov/pubmed/36601065
http://dx.doi.org/10.3389/fcvm.2022.1016126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806256/
https://www.ncbi.nlm.nih.gov/pubmed/36601065
http://dx.doi.org/10.3389/fcvm.2022.1016126

Ejemplares similares